ATE467124T1 - Mit prp sp sc/sp wechselwirkende moleküle und deren verwendung - Google Patents

Mit prp sp sc/sp wechselwirkende moleküle und deren verwendung

Info

Publication number
ATE467124T1
ATE467124T1 AT03754894T AT03754894T ATE467124T1 AT E467124 T1 ATE467124 T1 AT E467124T1 AT 03754894 T AT03754894 T AT 03754894T AT 03754894 T AT03754894 T AT 03754894T AT E467124 T1 ATE467124 T1 AT E467124T1
Authority
AT
Austria
Prior art keywords
prp
molecules interacting
sup
peptides
features
Prior art date
Application number
AT03754894T
Other languages
English (en)
Inventor
Neil Cashman
Eustache Paramithiotis
Boissiere Sylvie La
Robert Lawton
Greg Francoeur
Lisa Estey
Marc Pinard
Original Assignee
Idexx Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idexx Lab Inc filed Critical Idexx Lab Inc
Application granted granted Critical
Publication of ATE467124T1 publication Critical patent/ATE467124T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2828—Prion diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT03754894T 2002-09-27 2003-09-26 Mit prp sp sc/sp wechselwirkende moleküle und deren verwendung ATE467124T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/256,538 US20040072236A1 (en) 2002-09-27 2002-09-27 PrPSc -interacting molecules and uses thereof
PCT/US2003/030273 WO2004029072A2 (en) 2002-09-27 2003-09-25 PrPsc -INTERACTING MOLECULES AND USES THEREOF

Publications (1)

Publication Number Publication Date
ATE467124T1 true ATE467124T1 (de) 2010-05-15

Family

ID=32041771

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03754894T ATE467124T1 (de) 2002-09-27 2003-09-26 Mit prp sp sc/sp wechselwirkende moleküle und deren verwendung

Country Status (7)

Country Link
US (2) US20040072236A1 (de)
EP (1) EP1575989B1 (de)
JP (1) JP4533750B2 (de)
AT (1) ATE467124T1 (de)
CA (1) CA2500120A1 (de)
DE (1) DE60332488D1 (de)
WO (1) WO2004029072A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041807B1 (en) 1999-06-23 2006-05-09 Caprion Pharmaceuticals, Inc. Antibodies to a YYX epitope of a mammalian prion protein
JP4235544B2 (ja) 2001-05-31 2009-03-11 アドライフ インコーポレーティッド 欠陥折畳み蛋白質センサー方法
US20050026165A1 (en) * 2001-05-31 2005-02-03 Cindy Orser Detection of conformationally altered proteins and prions
US20040072236A1 (en) 2002-09-27 2004-04-15 Neil Cashman PrPSc -interacting molecules and uses thereof
WO2004091523A2 (en) * 2003-04-14 2004-10-28 American National Red Cross Method for identifying ligands specific for structural isoforms of proteins
KR101166012B1 (ko) 2003-08-13 2012-07-23 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 프리온-특이적 펩티드 시약
US20060035242A1 (en) * 2004-08-13 2006-02-16 Michelitsch Melissa D Prion-specific peptide reagents
US20060057671A1 (en) * 2004-09-10 2006-03-16 Orser Cindy S Immobilized probes and methods of detecting conformationally altered prion proteins
US7328063B2 (en) * 2004-11-30 2008-02-05 Cardiac Pacemakers, Inc. Method and apparatus for arrhythmia classification using atrial signal mapping
WO2006076687A2 (en) * 2005-01-13 2006-07-20 Novartis Vaccines And Diagnostics Inc. Elisa assays using prion-specific peptide reagents
WO2006076683A2 (en) * 2005-01-13 2006-07-20 Novartis Vaccines And Diagnostics Inc. Isolation and detection of pathogenic prions
BRPI0607350A2 (pt) * 2005-02-15 2009-09-01 Adlyfe Inc método para detecção da presença ou quantidade de uma proteìna erroneamente duplicada em uma amostra e kit
ES2404940T3 (es) * 2005-09-09 2013-05-29 Novartis Ag Reactivos de peptoide específicos para prión
JP4769925B2 (ja) * 2006-03-15 2011-09-07 国立大学法人東北大学 異常型プリオン蛋白質の濃縮方法、および除去方法
US7601506B2 (en) * 2006-07-28 2009-10-13 Idexx Laboratories, Inc. Identification of leucocytes bearing diagnostic markers for transmissible spongiform encephalopathies
EP2156181B1 (de) * 2006-07-28 2015-11-04 Adlyfe, Inc. Peptidsonden für diagnostik und therapie
CA2675039A1 (en) * 2007-01-12 2008-07-17 Alicon Ag Method for removing prion protein
CA2721833A1 (en) * 2008-04-25 2009-10-29 Scott Napper Prion immunogenic peptides and repeats thereof
JP2011520108A (ja) * 2008-04-30 2011-07-14 ノバルティス アーゲー 病原性配座異性体についてのアッセイ
US20120009209A1 (en) * 2010-06-10 2012-01-12 The Regents Of The University Of California Enrichment and purification of infectious prion proteins
MX2013002870A (es) 2010-09-13 2013-06-18 Abbvie Inc Ensayo de deteccion residual de anticuerpo monoclonal altamente sensible.

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI90990C (fi) * 1984-12-18 1994-04-25 Boehringer Ingelheim Int Rekombinantti-DNA-molekyyli, transformoitu isäntäorganismi ja menetelmä interferonin valmistamiseksi
ATE127923T1 (de) 1986-04-30 1995-09-15 Igen Inc Elektrochemilumineszenz-testverfahren.
SU1529119A1 (ru) 1987-04-20 1989-12-15 Белорусский научно-исследовательский институт эпидемиологии и микробиологии Способ определени нейровирусов в спинномозговой жидкости
US4806627A (en) * 1987-05-29 1989-02-21 Research Foundation Of Mental Hygiene Inc. Hybrid cell lines producing monoclonal antibodies dircted against scrapie-associated fibril proteins
WO1992006220A1 (en) 1990-10-05 1992-04-16 President And Fellows Of Harvard College Detection and isolation of ligands
ATE168131T1 (de) 1990-10-30 1998-07-15 Jolla Cancer Res Found T-cadherin-bindungsmolekül
DK0616613T3 (da) * 1991-12-03 1999-09-27 Proteus Molecular Design Fragmenter af prionprotein
CA2111573C (en) * 1992-04-17 2002-11-26 Shintaro Suzuki Cadherin materials and methods
US5597725A (en) * 1992-04-17 1997-01-28 Doheny Eye Institute Cadherin-specific antibodies and hybridoma cell lines
US5646250A (en) * 1992-04-17 1997-07-08 Doheny Eye Institute Cadherin polypeptides
AU4376093A (en) 1992-05-15 1993-12-13 Instituto Nazionale Neurologico C. Besta Soluble prion polypeptides, and methods for detecting and purifying thereof
US5276059A (en) 1992-07-10 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of diseases associated with amyloid formation
US5643781A (en) * 1992-12-29 1997-07-01 Doheny Eye Institute DNA encoding protocadherin-42
US5798224A (en) 1992-12-29 1998-08-25 Doheny Eye Institute Nucleic acids encoding protocadherin
US5679530A (en) 1995-04-12 1997-10-21 Ludwig Institute For Cancer Research Isolated protein having molecular weight of from about 55 kilodaltons to about 65 kilodaltons (SDS-page) which binds to prion protein
US5948763A (en) 1995-06-07 1999-09-07 New York University Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits
DE852011T1 (de) * 1995-09-14 2001-10-11 Scripps Res Inst La Jolla Für natives prp-sc spezifische antikörper
US5750361A (en) * 1995-11-02 1998-05-12 The Regents Of The University Of California Formation and use of prion protein (PRP) complexes
WO1997043649A1 (en) 1996-05-14 1997-11-20 Winnacker Ernst Ludwig CHARPERONES CAPABLE OF BINDING TO PRION PROTEINS AND DISTINGUISHING THE ISOFORMS PrPc AND PrP?sc¿
BR9709900A (pt) * 1996-05-29 2000-01-25 Univ Mcgill Proteìnas de ligacão de proteìnas de prìons e usos das mesmas.
EP0861900A1 (de) 1997-02-21 1998-09-02 Erziehungsdirektion Of The Canton Zurich Immunologischer Nachweis von Prionen
US5891641A (en) * 1997-02-21 1999-04-06 The Regents Of The University Of California Assay for disease related conformation of a protein
DE19741607A1 (de) 1997-09-20 1999-03-25 Prionics Ag Synthetische Polypeptide zur Diagnose und Therapie von Prionerkrankungen
US6165784A (en) 1997-10-14 2000-12-26 The United States Of America As Represented By The Secretary Of Agriculture Antibodies for the detection of prion protein as an indication of transmissible spongiform encephalopathies
EP1057022B1 (de) 1998-02-20 2003-07-09 The Regents Of The University Of California Assay für spezifische stämme von mit mehreren krankheiten zusammenhängenden proteinkonformationen
US6211149B1 (en) * 1998-08-03 2001-04-03 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors of formation of protease resistant prion protein
GB2348203B (en) * 1998-11-04 2002-06-19 Imp College Innovations Ltd Solube beta-forms of prion proteins, methods of preparation and use
ES2278617T3 (es) * 1999-06-23 2007-08-16 Idexx Laboratories Inc Peptidos de proteinas de prion y sus usos.
EP1210110A4 (de) * 1999-06-29 2003-03-19 Univ Mcgill An prionprotein bindende proteine und deren verwendungen
IL152116A0 (en) * 2000-04-05 2003-05-29 Vi Technologies Inc Prion-binding ligands and methods of using same
DE10230141B4 (de) * 2002-07-04 2004-07-15 Priontype Gmbh Verfahren und Kit zur Anreicherung und zum Nachweis von veränderten Prion-Proteinen (PrPSc)
US20040072236A1 (en) 2002-09-27 2004-04-15 Neil Cashman PrPSc -interacting molecules and uses thereof

Also Published As

Publication number Publication date
AU2003272695A1 (en) 2004-04-19
US20060183156A1 (en) 2006-08-17
EP1575989B1 (de) 2010-05-05
JP4533750B2 (ja) 2010-09-01
CA2500120A1 (en) 2004-04-08
WO2004029072A3 (en) 2005-12-15
EP1575989A4 (de) 2007-05-16
JP2006507484A (ja) 2006-03-02
EP1575989A2 (de) 2005-09-21
US20040072236A1 (en) 2004-04-15
WO2004029072A2 (en) 2004-04-08
US7435540B2 (en) 2008-10-14
DE60332488D1 (de) 2010-06-17

Similar Documents

Publication Publication Date Title
ATE467124T1 (de) Mit prp sp sc/sp wechselwirkende moleküle und deren verwendung
ATE541590T1 (de) Modifizierte antikörper-fragmente
DE60032486D1 (de) Prion protein peptide und deren verwendung
WO2005018424A3 (en) Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits
ATE490275T1 (de) Antikörper gegen interleukin-22 und verwendungen dafür
CY1112055T1 (el) Συνθεσεις και μεθοδοι για την διαγνωση και θεραπευτικη αγωγη ογκου πνευμονα
DE60130538D1 (de) Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung
DE69813158D1 (de) Assays zur Bestimmung von Proteinfragmenten in biologischen Medien
EP1480657A4 (de) Polymere zur abgabe von peptiden und kleinen molekülen in vivo i
EP1912674A4 (de) Bispezifische einzelketten-fv-antikörper-moleküle und anwendungsverfahren dafür
ATE492563T1 (de) Vollständige humane monoklonale antikörper gegen il-13
ATE382053T1 (de) System zur antikörperexpression und- synthese
CY1116256T1 (el) Il-17 ανταγωνιστικα αντισωματα
ATE424560T1 (de) Marker für neuromyelitis optica
DE60321041D1 (de) Antikörper gegen krebsantigen tmeff2 und seine anwendungen
CY1110848T1 (el) Αντισωμα αντι ανθρωπου νοgo α kai h φαρμακευτικη του χρηση
DE60207254D1 (de) Natürlicher ligand von gpcr chemr23 und dessen verwendung
DE602005026169D1 (de) Tetrahydroisochinolinverbindungen zur behandlung von zns-erkrankungen
DE502005009389D1 (de) Identifizierung und charakterisierung von funktionsblockierenden anti-ed-b-fibronektin antikörpern
ATE417605T1 (de) Proteine die cross-beta-struktur enthaltendes amyloid binden, sowie verfahren zur modulation der cross-beta-struktur, ihrer bildung und der damit zusammenhängenden toxizität
EA200500064A1 (ru) Многофункциональные маркеры продуктов и способы их получения и применения
DE69433243D1 (de) Verwendunf von ApoE zum Binden von TAU und MAP2c Proteinen und zur Behandlung von Alzheimer's Krankheit
BR0014626A (pt) Análise de leptina
DE60332481D1 (de) Peptide und deren verwendung in der behandlung von krankheiten des zentralen nervensystems
WO2003027251A3 (en) Novel molecules of the pyrin domain protein family and uses thereof

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties